MicrofluidX secures £3.3m Series A from Longwall Ventures and other backers to advance cell culture platforms.
The Stevenage enterprise raised the capital from Longwall Ventures and a syndicate of backers to fund trials and product development.
MicrofluidX develops next-generation bioreactors and scalable cell culture platforms for advanced research and manufacturing.
Stevenage-based MicrofluidX has secured £3.3m in a Series A financing round led by Longwall Ventures. The company develops scalable bioreactor technology designed to improve cell and gene therapy manufacturing. Additional participants in the round include UKI2S, Perscitus, J.B. Ugland Venture AS, Puffin Point, and Esco LifeSciences, bringing the firm total funding to £7m. The capital will support ongoing product development and external trials with end users.
From the founder
"Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,"
Antoine Espinet
CEO at MicrofluidX
Investor perspective
"We’ve been really impressed by how quickly the MicrofluidX team have developed their exciting technology platform and proved its potential,"
Rebecca Todd
Investment Director, Longwall
Use of funds
- 01Continue product development
Investors
Rebecca Todd
Longwall
Oliver Sexton
UKI2S
Charles Shorthand
Perscitus
Richard Coulling
J.B. Ugland Venture AS
Puffin Point
Xiangliang Lin
Esco LifeSciences